Connect with us

Business

Boss of Newcastle skin health products firm quits following suspension

Published

on

Business Live

Stuart Ashman had been CEO of SkinBioTherapeutics since 2019, leading it through a period of growth including deals with high street retailers

The Core at Newcastle Helix.

The Core at Newcastle Helix where SkinBioTherapeutics is based.(Image: Newcastle Journal)

The CEO of Newcastle healthcare innovator SkinBioTherapeutics has resigned as an investigation into his conduct was about to be launched.

Stuart Ashman, an experienced life sciences executive, was suspended by the Helix-based firm’s board as the company has brought in advisers to carry out an investigation into “matters relating to his conduct”. The move was announced to investors on the London Stock Exchange, though few details were given.

Non executive chairman Martin Hunt has become executive chairman temporarily. The company said: “He will be supported by the rest of the board and leadership team to provide business leadership and continuity. The company has instigated a search to find an interim CEO to appoint as soon as possible, and to find a new, permanent CEO for the longer term.”

Mr Ashman had been at the helm of SkinBioTherapeutics since 2019. He has led a period of significant growth, including partnerships with pharmaceuticals giant Croda and deals with major retailer Superdrug, which have seen the Newcastle firm’s products hit high street shelves.

Advertisement

At full year results published in December, Mr Ashman said he expected 2026 to bring further revenue growth having seen revenue rise from £1.2m to £4.6m and a narrowing of operating losses from £2.9m to £1.1m in the year to the end of June 2025.

SkinBioTherapeutics’ offer is based around its SkinBiotix technology which uses the microbiome – the range of microorganisms living within the human body – to promote wound healing and reduce the risk of infection. The business has also been acquisitive with Mr Ashman leading.

In early 2024 it bought Cambridgeshire’s Dermatonics Limited in a deal that was said to provide cost synergies as well as the potential for a future development platform for advanced topical creams and capsules. Later that year, it also acquired Yorkshire-based Bio-Tech Solutions Ltd (BTS) – a manufacturer and supplier of health, hygiene and personal care products – for £1.25m.

Mr Ashman was previously CEO at Finnish medical device company Onbone, and before that president and CEO of Andover Healthcare Inc, a US-based wound management manufacturer. He was also president and CEO of UK medical engineering business TI Group and has held roles at BSN Medical and Smith & Nephew.

Advertisement
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Public Storage Q4 2025 slides: Leadership transition and PS4.0 strategy unveiled

Published

on

Public Storage Q4 2025 slides: Leadership transition and PS4.0 strategy unveiled


Public Storage Q4 2025 slides: Leadership transition and PS4.0 strategy unveiled

Continue Reading

Business

SternMaid America to focus on contract manufacturing, ingredients

Published

on

SternMaid America to focus on contract manufacturing, ingredients

Stern-Wywiol Group rebrands in the United States.

Continue Reading

Business

Lenovo Posts Record Revenue With Strong Device and AI Server Sales

Published

on

Lenovo Posts Record Revenue With Strong Device and AI Server Sales

Lenovo 992 2.89%increase; green up pointing triangle Group, the world’s largest personal-computer maker, maintained double-digit revenue growth in its third quarter as it continued solid device sales and AI server revenue strengthened.

The better-than-expected results come against a backdrop of surging memory-chip prices disrupting the consumer-electronics market as artificial-intelligence demand outpaces supply. Some consumers have also pulled forward demand, worried that rising memory prices would make electronics more expensive this year, likely giving the PC maker a bump.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading

Business

Olympus Q3 FY2026 slides: Revenue guidance cut 2% amid ship-hold challenges

Published

on

Olympus Q3 FY2026 slides: Revenue guidance cut 2% amid ship-hold challenges


Olympus Q3 FY2026 slides: Revenue guidance cut 2% amid ship-hold challenges

Continue Reading

Business

Welsh spinout firms are not getting the growth capital needed to fly

Published

on

Business Live

The number of Welsh spinouts firms have also fallen shows new research from UK Research and Innovation

John Atack and Simon Ward of Draig Therapeutics.

The new UK Research and Innovation report has revealed what too many Welsh founders already know – we create technology firms but struggle to finance them through the critical early stages. Too few are supported through to serious scale and this is especially true of those spinout businesses that are founded to take university research into the marketplace.

On initial reading, the report shows some good news, with Wales accounting for 3% of UK research income and producing 3.6% of UK university spinouts founded between 2013 and 2024, suggesting we may be punching above our weight in creating companies.

Advertisement

However, the bad news is that Welsh spinout formation has fallen from around 19 per year in 2013-15 to around seven per year in 2022-24, which means fewer bets, fewer shots on goal, and fewer companies reaching the stage where external capital can realistically back them.

READ MORE: Admiral acquires commercial fleet insurer fintech Flock in an £80m dealREAD MORE: How a £30m Cardiff Capital Region company contract to demolish Aberthaw Power Station was botched

This should worry anyone who cares about productivity, private sector job creation, or building home-grown firms. Indeed, here is where we should all pay attention, because the report’s figures are genuinely alarming.

While Wales generates 3.6% of UK spinouts, it captures only 1.4% of pre-seed and seed equity investment into spinouts, and an astonishing 0.1% of early-stage VC equity investment. In other words, while we create innovative businesses, they just don’t get the finance necessary to scale.

Advertisement

This is not a small gap but a massive market failure at the exact stage where spinouts transition from “clever science” to commercial execution i.e. building a product, hiring commercial leadership and pricing a serious seed round.

This is the phase where companies either become investable businesses or remain permanently “nearly ready,” and where momentum is either built or lost. If we are capturing virtually none of the early-stage venture capital equity going into spinouts, we are effectively saying they are not a strength of the economy and that Wales, through its Development Bank and other funders, is not properly backing our own potential when it needs it the most.

In fact, the biggest constraint, and one I have been highlighting in this column for two decades, is that Wales simply does not have enough experienced venture capital investors on the ground with the capability and appetite to lead rounds to back winners again and again with only 1.1% of venture capital firms having any office presence here in Wales (and that includes the Development Bank).

If you don’t have lead investors with the necessary expertise, you don’t just get fewer deals, you get weaker syndicates, smaller rounds, slower progress, and a higher risk that firms are pulled towards stronger ecosystems once they show promise. When that happens, Wales loses the long-term value created when a business finally scales.

Advertisement

Worst still, the report suggests that of the Welsh spinouts founded since 2013 and at least three years old, the majority have failed to raise at all: the worst performance in the UK. In addition, only one in 50 have secured later-stage venture capital rounds above £10m, i.e. a tiny proportion of university-born Welsh firms are reaching the funding thresholds associated with meaningful scale and long-term value creation.

That is scandalous. Those who are part of the funding ecosystem should not try to celebrate spinout formation and then quietly ignore the fact the majority go nowhere because there is insufficient capital being made available.

We know Wales is never going to outspend London, south east England or the east of England on venture capital but that is not the issue.

What is important is whether we can build our own coherent pathway that converts research-led potential into investable ventures and then into scaling businesses that stay and grow here.

Advertisement

Unfortunately, the evidence suggests we are failing at that test, and it is a shameful performance because it is not inevitable as Wales has universities generating commercialisable research and founders willing to take the leap. And while an outlier, the recent success of Draig Therapeutics, a recent spinout from Cardiff University that has received more than £100m in venture investment, shows the massive potential that exists within our academic institutions.

On the other hand, there have been no real spin-offs from the compound semiconductor sector in South Wales despite it receiving more than £500m of funding from public and private organisations. In addition, one of these funders – the Cardiff Capital Region – has its own £50m investment fund and yet despite operating alongside one of the UK’s most strategically significant deep tech clusters, it has made little impact on turning this investable innovation into businesses that scale.

This is despite the report showing that in the UK, semiconductors are a sector where spinouts dominate and if Wales is going to win in this vital industry, it typically wins through university commercialisation and scale finance which simply isn’t happening.

Therefore, a funding system that includes the Development Bank of Wales, the British Business Bank and the Cardiff Capital Region that cannot get companies from pre-seed to seed, and from seed to meaningful growth, is inadequate at best. At worst, it becomes a machine for producing failure with talented founders wasting time, universities burning credibility, and taxpayers subsidising activity that does not translate into long-term value.

Advertisement

We need to face the reality caused by those funding Welsh businesses, namely that most Welsh spinouts go nowhere due to a lack of capital. In the absence of any meaningful private venture capital, we need our economic development bodies to build a coherent funding pathway.

Only when we commit resources to doing that properly and create a group of sustainable technology-based scaling firms that create wealth and well-paid jobs in Wales, can anyone claim that our spinouts are a strength and that innovation from our universities are the engine growing the economy.

Continue Reading

Business

California’s wealthy eye Las Vegas as proposed wealth tax looms

Published

on

California’s wealthy eye Las Vegas as proposed wealth tax looms

High-net-worth Californians are increasingly setting their sights on Las Vegas as they look to reduce their tax burden and protect their finances as a proposed wealth tax looms in the Golden State. 

New data shows that by the end of 2025, more than 23% of Realtor.com listing views for Las Vegas homes came from Los Angeles, making it the leading source of out-of-market interest.

Advertisement

San Jose accounted for more than 8% of views, while Riverside, California, made up nearly 4%, according to Realtor.com.

“Migration from California to Las Vegas may reflect both tax considerations and the meaningful affordability gap between the two markets,” Realtor.com senior economic research analyst Hannah Jones told FOX Business in an email.

MARK ZUCKERBERG BECOMES LATEST CALIFORNIA BILLIONAIRE TO RELOCATE TO FLORIDA AMID TAX CONCERNS

Los Angeles city skyline during the day

A view of the Los Angeles city skyline is seen here. (Simonkr / Getty Images)

That gap is substantial. Los Angeles’ typical home price topped $1 million in January, while San Jose’s median listing price was even higher at $1.1 million. 

Advertisement

In contrast, Las Vegas’ median listing price stood at $465,000, according to Realtor.com.

Nevada’s lack of a state income tax also remains a major draw, Jones said.

“Taxes and overall cost of living are major drivers, and Nevada’s lack of state income tax continues to be one of the most frequently cited reasons for the move,” Jones said. 

“For some clients, it’s purely financial. They can sell a $2 million to $3 million home in California and purchase a comparable or larger property in Las Vegas for less while reducing their ongoing tax burden.”

Advertisement

HOMEBUYERS GAIN UPPER HAND IN 3 MAJOR CITIES AS INVENTORIES GROW

Las Vegas Strip Bellagio Water Fountain Show

The Bellagio Water Fountain Show is viewed from Caesars Palace Hotel & Casino on May 29, 2025, in Las Vegas, Nevada. (George Rose/Getty Images)

The migration trend also comes as California considers a proposed wealth tax that would impose a one-time 5% tax on the net worth of residents with assets exceeding $1 billion.

The measure, backed by the Service Employees International Union–United Healthcare Workers West, would need roughly 875,000 signatures to qualify for the November ballot.

California Gov. Gavin Newsom has opposed the measure, warning it could push high earners to leave the state.

Advertisement

“While policy discussions like a potential wealth tax may influence timing for some high-income households, the ability to convert expensive coastal real estate into greater purchasing power in a lower-cost market is likely also a significant driver,” Jones told FOX Business. 

BILLIONAIRES FLEE CALIFORNIA ‘WITHIN SEVEN DAYS’ OVER PROPOSED WEALTH TAX: INSIDE THE MIAMI MIGRATION

California Governor Gavin Newsom gives speech

California Gov. Gavin Newsom speaks during a rally on Nov. 8, 2025, in Houston, Texas. (Brandon Bell/Getty Images)

“Together, these financial incentives are helping sustain cross-state housing demand.”

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Advertisement

Meta CEO Mark Zuckerberg and his wife, Priscilla Chan, are buying a waterfront mansion in Miami’s exclusive “Billionaire Bunker,” becoming the latest high-profile California billionaire to establish roots in Florida amid tax concerns.

FOX Business’ Kristen Altus contributed to this report.

Continue Reading

Business

Form 6K BANCO BILBAO VIZCAYA ARGENTARIA For: 13 February

Published

on


Form 6K BANCO BILBAO VIZCAYA ARGENTARIA For: 13 February

Continue Reading

Business

Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Q4: 2026-02-06 Earnings Summary

EPS of $1.99 beats by $0.37

 | Revenue of $2.28B (-7.14% Y/Y) beats by $75.58M

Biogen Inc. (BIIB) Piper Sandler Virtual Novel Targets in Immunology Symposium February 13, 2026 10:30 AM EST

Company Participants

Diana Gallagher – Head of AD, MS & Immunology Development Units

Advertisement

Conference Call Participants

David Amsellem – Piper Sandler & Co., Research Division

Advertisement

Presentation

David Amsellem
Piper Sandler & Co., Research Division

Okay, good morning, everyone. And as I keep saying this morning, happy Friday the 13th, but on a serious note, we’re delighted to be hosting our Virtual Immunology Symposium. This is David Amsellem from the Piper Sandler Biopharma Research Team. And we’re delighted to have Biogen with us for the next 25 minutes or so. So we have Dr. Diana Gallagher. She is the Head of Clinical Development for MS Immunology and Alzheimer’s. So thanks so much, Diana, for taking the time to chat with us.

Certainly, there’s a great deal going on regarding Biogen’s immunology pipeline and some late-stage readouts that are coming.

Advertisement

Question-and-Answer Session

David Amsellem
Piper Sandler & Co., Research Division

Advertisement

Maybe I’ll start with your lupus programs. So you have dapirolizumab and litifilimab, both in late-stage development. But I wanted to ask a high-level question on the strategic rationale of prioritizing lupus, specifically SLE and other manifestations of the disease given that it’s historically been such a challenging space in terms of drug development. So I guess with that in mind, why such a big priority to lupus? Obviously, it’s a major unmet medical need. But just given the challenges, maybe talk about your thought process here.

Diana Gallagher
Head of AD, MS & Immunology Development Units

Sure. So we’ve been working — first of all, thanks for having me, David. We’re really excited to be here. And you’re right, lupus remains a very underserved, heterogeneous disease area, major unmet need, where patients need more treatment options. We have been working in lupus. It’s not new for

Advertisement
Continue Reading

Business

Dauch Corporation (DCH) Q4 2025 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Dauch Corporation (DCH) Q4 2025 Earnings Call February 13, 2026 10:00 AM EST

Company Participants

David Lim – Head of Investor Relations
David Dauch – Chairman & CEO
Chris May – Executive VP & CFO

Conference Call Participants

Advertisement

Joseph Spak – UBS Investment Bank, Research Division
Thomas Ito
Thomas Scholl – BNP Paribas, Research Division
Yan Dong – Deutsche Bank AG, Research Division
Itay Michaeli – TD Cowen, Research Division

Presentation

Operator

Advertisement

Good morning. My name is Jamie, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the Dauch Corporation Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, today’s event is being recorded.

I would now like to turn the floor over to Mr. David Lim, Head of Investor Relations. Please go ahead, Mr. Lim.

David Lim
Head of Investor Relations

Advertisement

Thank you, and good morning. I’d like to welcome everyone who is joining us on Dauch Corporation’s fourth quarter earnings call. Earlier this morning, we released our fourth quarter of 2025 earnings announcement. You can access this announcement on the Investor Relations page of our website, www.dauch.com and through the PR Newswire services. You can also find supplemental slides for this conference call on the investor page of our website as well. To listen to the replay of this call, you can dial (855) 669-9658, replay access code 577-1070. This replay will be available through February 20.

As for the upcoming investor conferences, we’ll be at the JPMorgan 2026 Global Leverage Finance Conference on March 3, and we will also attend the Bank of America 2026 Global Automotive Summit on March 17. We look forward to seeing you there.

Now before we begin, I’d like to remind everyone that the matters discussed in this call today may contain comments and forward-looking statements

Advertisement
Continue Reading

Business

The Wendy’s Company (WEN) Q4 2025 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Operator

Good morning. Welcome to The Wendy’s Company Earnings Results Conference Call [Operator Instructions] Thank you. You may begin your conference.

Aaron Broholm
Head of Investor Relations

Advertisement

Good morning, and thank you for joining our fiscal 2025 fourth quarter earnings conference call. After this brief introduction, Ken Cook, Interim Chief Executive Officer and Chief Financial Officer, will provide a business update; and then Suzie Thuerk, Chief Accounting Officer and Global Head of FP&A, will review our fourth quarter results, share capital allocation priorities and our 2026 outlook. From there, we will open up the line for questions.

Today’s conference call and webcast includes a presentation, which is available on our Investor Relations website, ir.wendys.com. Before we begin, please take note of the safe harbor statement that appears at the end of today’s earnings release. This disclosure reminds investors that certain information we discuss today is forward-looking and reflects our current expectations about future plans and performance. Various factors could affect our results and cause those results to differ materially from the projections set forth in our forward-looking statements.

Also, some of today’s comments will

Advertisement
Continue Reading

Trending

Copyright © 2025